Tennor Therapeutics priced an $80 million IPO in Hong Kong to fund its antibacterial pipeline, with the lead asset rifasutenizol (TNP-2198) positioned for a potential first targeted combination regimen for H. pylori. The company is awaiting China NMPA approval and expects a decision later in 2026, according to its securities filing.